| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | 1,667,298 | 3,944,111 | NaN | 0 |
| Cost of revenues | 328,878 | 789,208 | NaN | NaN |
| Gross profit | 1,338,420 | 3,154,903 | NaN | NaN |
| Research and development | 1,633,518 | 1,599,719 | 1,641,586 | 1,621,325 |
| Amortization of in-process research and development | 1,720,312 | 573,438 | NaN | NaN |
| General and administrative | 26,391,101 | 5,720,727 | 3,905,961 | 4,447,008 |
| Stock-based compensation general and administrative | 3,788,275 | 4,280,227 | 2,889,762 | 2,719,674 |
| Total operating expenses | 33,533,206 | 12,174,111 | 8,437,309 | 8,788,007 |
| Operating loss | -32,194,786 | -9,019,208 | -8,437,309 | -8,788,007 |
| Interest income | 53,584 | 45,097 | 53,423 | 20,637 |
| Gain on sale of new jersey net operating losses | 3,833,277 | NaN | NaN | NaN |
| Interest expense | 33,031 | 155,538 | 95,520 | 172,262 |
| Gain on sale of new jersey net operating losses | NaN | NaN | NaN | 0 |
| Total other income, net | 3,853,830 | -110,441 | -42,097 | -151,625 |
| Loss before income taxes | -28,340,956 | -9,129,649 | -8,479,406 | -8,939,632 |
| Income tax expense (benefit) | -231,210 | 264,240 | 264,240 | 264,240 |
| Net loss | -28,109,746 | -9,393,889 | -8,743,646 | -9,203,872 |
| Net loss attributable to non-controlling interest | -6,878,606 | -1,173,104 | -784,358 | -414,000 |
| Deemed dividend on warrant extension | NaN | NaN | NaN | 0 |
| Net loss applicable to common stockholders | -21,231,140 | -8,220,785 | -7,959,288 | -8,789,872 |
| Basic EPS | -0.95 | -0.38 | -0.463 | -0.8 |
| Diluted EPS | -0.95 | -0.38 | -0.463 | -0.8 |
| Basic Average Shares | 22,376,427 | 21,495,274 | 17,180,337 | 11,006,896 |
| Diluted Average Shares | 22,376,427 | 21,495,274 | 17,180,337 | 11,006,896 |
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc. (CTXR)